Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T; FHU ACRONIM. Kostine M, et al. Among authors: tison a. Eur J Cancer. 2021 Nov;157:474-484. doi: 10.1016/j.ejca.2021.08.036. Epub 2021 Oct 11. Eur J Cancer. 2021. PMID: 34649118 Free article.
[18F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica.
Allard B, Devauchelle-Pensec V, Saraux A, Nowak E, Tison A, Boukhlal S, Guellec D, Jousse-Joulin S, Cornec D, Marhadour T, Le Pennec R, Salaün PY, Querellou S. Allard B, et al. Among authors: tison a. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1297-1309. doi: 10.1007/s00259-023-06557-x. Epub 2023 Dec 14. Eur J Nucl Med Mol Imaging. 2024. PMID: 38095675
Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation.
Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, Hillion S, Roguedas-Contios AM, Benyoussef AA, Alarcon-Riquelme ME, Pers JO, Devauchelle-Pensec V; PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium. Bettacchioli E, et al. Among authors: tison a. Arthritis Rheumatol. 2024 May;76(5):751-762. doi: 10.1002/art.42789. Epub 2024 Feb 14. Arthritis Rheumatol. 2024. PMID: 38130019
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Tison A, et al. Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31379105
Reply.
Tison A, Kostine M, Cornec D. Tison A, et al. Arthritis Rheumatol. 2020 Mar;72(3):506-508. doi: 10.1002/art.41139. Epub 2020 Jan 6. Arthritis Rheumatol. 2020. PMID: 31609501 No abstract available.
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis.
Veccia A, Kostine M, Tison A, Dipasquale M, Kinspergher S, Prokop L, Grandi G, Inchiostro S, Caffo O, Paolazzi G, Bortolotti R, Cornec D, Berti A. Veccia A, et al. Among authors: tison a. Joint Bone Spine. 2022 Jul;89(4):105403. doi: 10.1016/j.jbspin.2022.105403. Epub 2022 May 1. Joint Bone Spine. 2022. PMID: 35508288
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Ladouceur A, Barnetche T, Mouterde G, Tison A, Bitoun S, Prey S, Dutriaux C, Gerard E, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R, Domblides C, Daste A, Gross-Goupil M, Sionneau B, Lefort F, Larroquette M, Richez C, Truchetet ME, Schaeverbeke T, Kostine M. Ladouceur A, et al. Among authors: tison a. RMD Open. 2023 Nov 29;9(4):e003795. doi: 10.1136/rmdopen-2023-003795. RMD Open. 2023. PMID: 38030233 Free PMC article.
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica.
Liew DFL, Mackie SL, Tison A, Sattui SE, Yates M, Buchanan RRC, Owen CE. Liew DFL, et al. Among authors: tison a. Rheum Dis Clin North Am. 2024 May;50(2):255-267. doi: 10.1016/j.rdc.2024.02.001. Rheum Dis Clin North Am. 2024. PMID: 38670724 Review.
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Avouac J, et al. Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25. Lancet Rheumatol. 2021. PMID: 33786454 Free PMC article.
34 results